bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
This study intends to evaluate the efficacy and safety of blank- microsphere transcatheter
arterial embolization-hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil
and leucovorin (bTAE-HAIC) plus Lenvatinib and Camrelizumab for patients with infiltrative
hepatocellular carcinoma.